U.S. National Institutes of Health
Last Updated: 05/29/08

Pharmacogenetics Research Network/The Breast Cancer Intergroup/National Cancer Institute Summit

March 30-31, 2008

Agenda

Sunday, March 30, 2008 Evening
8:00-9:15 PM SESSION I: Welcome and Introduction Speaker
8:00-8:10 Welcome and Overview of Objectives and Agenda Dan Hayes
8:10-8:40 Overview of Pharmacogenomics Richard Weinshilboum
8:40-8:50 Overview of PGRN Rochelle Long
8:50-9:00 Overview of PGRN Cancer Working Group Howard McLeod
9:00-9:15 Overview of TBCI, CSC, and Specimen Resources Dan Hayes

 

Monday, March 31, 2008, Full Day
8:00-10:30 AM SESSION II: PGRN Accomplishments to Date in Cancer Speaker
8:00-8:25 Breast Cancer Pharmacogenomics/COBRA David Flockhart/COBRA
8.25-8.35 SNP analysis in FFPE tissue James Rae/COBRA
8:35-9:00 CYP2D6/Tamoxifen, Aromatase Inhibitors/May Additional Materials Matt Goetz & Jim Ingle/Mayo
9:00-9:30 Pharmacogenomic Advances in ALL/St. Judes Mary Relling/PAAR
9:30-10:00 Adult Solid Tumors Howard McLeod/CREATE
10:00-10:30 AM Break  
10:30-12:00 PM SESSION III: Pharmacogenomics in Cooperative Group Breast Cancer-what's happening now? Speaker
10.30-10.45 CALGB 40101 and others Deanna Kroetz
10.45-11.00 ECOG E2100 Bryan Schneider
11.00-11.15 NCIC CTG MA27/NCCTG initiatives Jim Ingle
11:15-11:30 NCIC other Geoffrey Liu
11.30-11.45 SWOG S8869 & SWOG S0221 Dan Hayes for Christine Ambrosone
11.45-12:00 SWOG S0226 Susan Nowell
12:00-1:00 PM Lunch
1:00-2:30 SESSION IV: Methods/Techniques/Infrastructure Speaker
1:00-1:15 Best Practices/Funding Sources, NCI program announcement Jo Anne Zujewski & Andy Freedman/NCI
1:15-2:30 PM SESSION V: Overview of Methods and Techniques Speaker
1:15-1:35 Association Studies in the Human Genome: Tatiana Foroud/COBRA
1:35-1:50 Whole Genome Analysis: techniques and pitfalls Todd Skaar/COBRA
1:50-2:10 Statistical and Bioinformatic Considerations Lang Li/COBRA
2:10-2:30 WGA: What it can do and what it can't Jerry Rotter/PARC
2:30-3:30 PM SESSION VI: Discussion Speaker
 

Are there studies that can be done now using Archived Cooperative Group specimens?
Germ line (WBC) DNA
Immortalized Cell lines (germ line DNA and espression)
Somatic specimens (tumor)
Using individual Group Specimens (not Intergroup)

Additional Questions:
1) Should we institute routine prospective collection of specimens for future clinical trials within TBCI and within individual Cooperative Group studies?
2) Should all Intergroup protocols and consent form templates be changed?
3) Should we design prospective clinical trials using pharmacogenomics to guide therapy